Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Clinical Trials, Metastatic Castration Resistant Prostate Cancer (MCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT03866382
Phase: Phase 2
Trial Summary: This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that that has spread f – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)
Acronym:

Pin It on Pinterest